The exclusion of the PBS and other funding processes and decisions from administrative review is confounded by proposals to significantly expand the remit and power of health technology assessment advisory committees.
If the Government expands their power, they need to be made more accountable
March 25, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech -
CSL executive Elizabeth Rex joins AusBiotech board as observer
June 22, 2026 - - Latest News -
It seems that one critical stakeholder group is missing in this website design
June 22, 2026 - - Latest News -
May 2026 delivers paediatric dosing flexibility, vaccine decisions, and policy updates
June 22, 2026 - - Latest News


